ADRB2 and glaucoma: Due to potent binding of the non-subtype-selective β-AR antagonist, timolol, and some β2-AR antagonists to β-ARs on ciliary processes in radioligand binding studies, and potent lowering of intraocular pressure in various species, β2-ARs are a pharmacological target in glaucoma treatment [65,66,67,68].